WARREN, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ), a clinical-stage speci…
Raanana, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech c…
Investigational REGN7508 (catalytic domain) and REGN9933 (A2 domain) are being evaluated for their potential to control thrombosis while minim…
OCU410 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reported, such as exu…
Bioxodes has enrolled first 16 patients in trial with BIOX-101Completing treatment of first cohort of patients will trigger interim analysisBI…
PASADENA, Calif.--(BUSINESS WIRE)--Dec 18, 2024--
- Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies - STONY BROOK, NY / ACCESSWIRE / December 18, 2024 /Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or ...
- Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies -
CAMBRIDGE, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Neutrolis Inc., a clinical stage biotech company focused on targeting Neutrophil Extracell…
NEW YORK--(BUSINESS WIRE)--Dec 18, 2024--
